• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Jennifer R Rider, ScD


  • Flavin R, Pettersson A, Hendrickson WK, Fiorentino M, Finn S, Kunz L, Judson GL, Lis R, Bailey D, Fiore C, Nuttall E, Martin NE, Stack E, Penney KL, Rider JR, Sinnott J, Sweeney C, Sesso HD, Fall K, Giovannucci E, Kantoff P, Stampfer M, Loda M, Mucci LA.SPINK1 Protein Expression and Prostate Cancer Progression.Clin Cancer Res. 2014 Mar 31.
  • Markt SC, Rider JR, Penney KL, Schumacher FR, Epstein MM, Fall K, Sesso HD, Stampfer MJ, Mucci LA.Genetic variation across C-reactive protein and risk of prostate cancer.Prostate. 2014 Jul;74(10):1034-42.
  • Bill-Axelson A, Holmberg L, Garmo H, Rider JR, Taari K, Busch C, Nordling S, Häggman M, Andersson SO, Spångberg A, Andrén O, Palmgren J, Steineck G, Adami HO, Johansson JE.Radical prostatectomy or watchful waiting in early prostate cancer.N Engl J Med. 2014 Mar 6;370(10):932-42.
  • Pettersson A, Lis RT, Meisner A, Flavin R, Stack EC, Fiorentino M, Finn S, Graff RE, Penney KL, Rider JR, Nuttall EJ, Martin NE, Sesso HD, Pollak M, Stampfer MJ, Kantoff PW, Giovannucci EL, Loda M, Mucci LA.Modification of the association between obesity and lethal prostate cancer by TMPRSS2:ERG.Journal of the National Cancer Institute. 2013 Dec 18;105(24):1881-90.
  • Sharma J, Gray KP, Evan C, Nakabayashi M, Fichorova R, Rider J, Mucci L, Kantoff PW, Sweeney CJ.Elevated insulin-like growth factor binding protein-1 (IGFBP-1) in men with metastatic prostate cancer starting androgen deprivation therapy (ADT) is associated with shorter time to castration resistance and overall survival.Prostate. 2013 Oct 16.
  • Penney KL, Stampfer MJ, Jahn JL, Sinnott JA, Flavin R, Rider JR, Finn S, Giovannucci E, Sesso HD, Loda M, Mucci LA, Fiorentino M.Gleason grade progression is uncommon.Cancer Res. 2013 Aug 15;73(16):5163-8.
  • Sigurdardottir LG, Valdimarsdottir UA, Mucci LA, Fall K, Rider JR, Schernhammer E, Czeisler CA, Launer L, Harris T, Stampfer MJ, Gudnason V, Lockley SW.Sleep disruption among older men and risk of prostate cancer.Cancer Epidemiol Biomarkers Prev. 2013 May;22(5):872-9.
  • Schoenfeld JD, Margalit DN, Kasperzyk JL, Shui IM, Rider JR, Epstein MM, Meisner A, Kenfield SA, Martin NE, Nguyen PL, Kantoff PW, Giovannucci EL, Stampfer MJ, Mucci LA.A single nucleotide polymorphism in inflammatory gene RNASEL predicts outcome after radiation therapy for localized prostate cancer.Clin Cancer Res. 2013 Mar 15;19(6):1612-9.
  • Bill-Axelson A, Garmo H, Holmberg L, Johansson JE, Adami HO, Steineck G, Johansson E, Rider JR.Long-term Distress After Radical Prostatectomy Versus Watchful Waiting in Prostate Cancer: A Longitudinal Study from the Scandinavian Prostate Cancer Group-4 Randomized Clinical Trial.Eur Urol. 2013 Feb 26.
  • Chen YC, Huang YL, Platz EA, Alderete JF, Zheng L, Rider JR, Kraft P, Giovannucci E, Sutcliffe S.Prospective study of effect modification by Toll-like receptor 4 variation on the association between Trichomonas vaginalis serostatus and prostate cancer.Cancer Causes Control. 2013 Jan;24(1):175-80.
  • Popiolek M, Rider JR, Andrén O, Andersson SO, Holmberg L, Adami HO, Johansson JE.Natural History of Early, Localized Prostate Cancer: A Final Report from Three Decades of Follow-up.Eur Urol. 2012 Oct 13.
  • Davidsson S, Ohlson AL, Andersson SO, Fall K, Meisner A, Fiorentino M, Andrén O, Rider JR.CD4 helper T cells, CD8 cytotoxic T cells, and FOXP3(+) regulatory T cells with respect to lethal prostate cancer.Mod Pathol. 2012 Oct 5.
  • Epstein MM, Edgren G, Rider JR, Mucci LA, Adami HO.Temporal trends in cause of death among Swedish and US men with prostate cancer.Journal of the National Cancer Institute. 2012 Sep 5;104(17):1335-42.
  • Rider JR, Sandin F, Andrén O, Wiklund P, Hugosson J, Stattin P.Long-term Outcomes Among Noncuratively Treated Men According to Prostate Cancer Risk Category in a Nationwide, Population-based Study.Eur Urol. 2012 Aug 10.
  • Sigurdardottir LG, Valdimarsdottir UA, Fall K, Rider JR, Lockley SW, Schernhammer E, Mucci LA.Circadian disruption, sleep loss, and prostate cancer risk: a systematic review of epidemiologic studies.Cancer Epidemiol Biomarkers Prev. 2012 Jul;21(7):1002-11.
  • Epstein MM, Andrén O, Kasperzyk JL, Shui IM, Penney KL, Fall K, Rider JR, Stampfer MJ, Andersson SO, Giovannucci E, Mucci LA.Seasonal variation in expression of markers in the vitamin D pathway in prostate tissue.Cancer Causes Control. 2012 Aug;23(8):1359-66.
  • Pettersson A, Graff RE, Bauer SR, Pitt MJ, Lis RT, Stack EC, Martin NE, Kunz L, Penney KL, Ligon A, Suppan C, Flavin R, Sesso H, Rider JR, Sweeney CS, Stampfer MJ, Fiorentino M, Kantoff PW, Sanda MG, Giovannucci E, Ding EL, Loda M, Mucci LA.The TMPRSS2:ERG Rearrangement, ERG Expression, and Prostate Cancer Outcomes: a Cohort Study and Meta-analysis.Cancer Epidemiol Biomarkers Prev. 2012 Jun 26.
  • Davidsson S, Fiorentino M, Andrén O, Fang F, Mucci LA, Varenhorst E, Fall K, Rider JR.Inflammation, focal atrophic lesions, and prostatic intraepithelial neoplasia with respect to risk of lethal prostate cancer.Cancer Epidemiol Biomarkers Prev. 2011 Oct;20(10):2280-7.
  • Dhillon PK, Penney KL, Schumacher F, Rider JR, Sesso HD, Pollack M, Fiorentino M, Finn S, Loda M, Rifai N, Mucci LA, Giovannucci EL, Stampfer MJ, Ma J.Common polymorphisms in the adiponectin and its receptor genes, adiponectin levels and the risk of prostate cancer.Cancer Epidemiol Biomarkers Prev. 2011 Sep 29.
  • Kirrander P, Kolaric A, Helenius G, Windahl T, Andrén O, Stark JR, Lillsunde-Larsson G, Elgh F, Karlsson M.Human papillomavirus prevalence, distribution and correlation to histopathological parameters in a large Swedish cohort of men with penile carcinoma.BJU Int. 2011 Aug;108(3):355-9.
  • Wilson KM, Kasperzyk JL, Rider JR, Kenfield S, van Dam RM, Stampfer MJ, Giovannucci E, Mucci LA.Coffee consumption and prostate cancer risk and progression in the Health Professionals Follow-up Study.Journal of the National Cancer Institute. 2011 Jun 8;103(11):876-84.
  • Penney KL, Sinnott JA, Fall K, Pawitan Y, Hoshida Y, Kraft P, Stark JR, Fiorentino M, Perner S, Finn S, Calza S, Flavin R, Freedman ML, Setlur S, Sesso HD, Andersson SO, Martin N, Kantoff PW, Johansson JE, Adami HO, Rubin MA, Loda M, Golub TR, Andrén O, Stampfer MJ, Mucci LA.mRNA expression signature of Gleason grade predicts lethal prostate cancer.J Clin Oncol. 2011 Jun 10;29(17):2391-6.
  • Shui IM, Stark JR, Penney KL, Schumacher FR, Epstein MM, Pitt MJ, Stampfer MJ, Tamimi RM, Lindstrom S, Sesso HD, Fall K, Ma J, Kraft P, Giovannucci E, Mucci LA.Genetic variation in the toll-like receptor 4 and prostate cancer incidence and mortality.Prostate. 2011 May 11.
  • Bill-Axelson A, Holmberg L, Ruutu M, Garmo H, Stark JR, Busch C, Nordling S, Häggman M, Andersson SO, Bratell S, Spångberg A, Palmgren J, Steineck G, Adami HO, Johansson JE, .Radical prostatectomy versus watchful waiting in early prostate cancer.N Engl J Med. 2011 May 5;364(18):1708-17.
  • Andersson SO, Andrén O, Lyth J, Stark JR, Henriksson M, Adami HO, Carlsson P, Johansson JE.Managing localized prostate cancer by radical prostatectomy or watchful waiting: Cost analysis of a randomized trial (SPCG-4).Scand J Urol Nephrol. 2011 Apr;45(3):177-83.
  • Meyer MS, Penney KL, Stark JR, Schumacher FR, Sesso HD, Loda M, Fiorentino M, Finn S, Flavin RJ, Kurth T, Price AL, Giovannucci EL, Fall K, Stampfer MJ, Ma J, Mucci LA.Genetic variation in RNASEL associated with prostate cancer risk and progression.Carcinogenesis. 2010 Sep;31(9):1597-603.
  • Fiorentino M, Judson G, Penney K, Flavin R, Stark J, Fiore C, Fall K, Martin N, Ma J, Sinnott J, Giovannucci E, Stampfer M, Sesso HD, Kantoff PW, Finn S, Loda M, Mucci L.Immunohistochemical expression of BRCA1 and lethal prostate cancer.Cancer Res. 2010 Apr 15;70(8):3136-9.
  • Mucci LA, Stark JR, Pollak MN, Li H, Kurth T, Stampfer MJ, Ma J.Plasma levels of acid-labile subunit, free insulin-like growth factor-I, and prostate cancer risk: a prospective study.Cancer Epidemiol Biomarkers Prev. 2010 Feb;19(2):484-91.
  • Stark JR, Judson G, Alderete JF, Mundodi V, Kucknoor AS, Giovannucci EL, Platz EA, Sutcliffe S, Fall K, Kurth T, Ma J, Stampfer MJ, Mucci LA.Prospective study of Trichomonas vaginalis infection and prostate cancer incidence and mortality: Physicians' Health Study.Journal of the National Cancer Institute. 2009 Oct 21;101(20):1406-11.
  • Stark JR, Mucci L, Rothman KJ, Adami HO.Screening for prostate cancer remains controversial.BMJ. 2009;339:b3601.
  • Mucci LA,Stark JR,Figg WD,Schumacher F,Li H,Abe M,Hennessy K,Stampfer MJ,Gaziano JM,Ma J,Kantoff PW.Polymorphism in endostatin, an angiogenesis inhibitor, and prostate cancer risk and survival: A prospective study.Int J Cancer. 2009 Sep 1;125(5):1143-6.
  • Stark JR,Perner S,Stampfer MJ,Sinnott JA,Finn S,Eisenstein AS,Ma J,Fiorentino M,Kurth T,Loda M,Giovannucci EL,Rubin MA,Mucci LA.Gleason Score and Lethal Prostate Cancer: Does 3 + 4 = 4 + 3?.J Clin Oncol. 2009 Jul 20;27(21):3459-64.
  • Stark JR, Wiklund F, Grönberg H, Schumacher F, Sinnott JA, Stampfer MJ, Mucci LA, Kraft P.Toll-like receptor signaling pathway variants and prostate cancer mortality.Cancer Epidemiol Biomarkers Prev. 2009 Jun;18(6):1859-63.
  • Stark JR,Li H,Kraft P,Kurth T,Giovannucci EL,Stampfer MJ,Ma J,Mucci LA.Circulating prediagnostic interleukin-6 and C-reactive protein and prostate cancer incidence and mortality.Int J Cancer. 2009 Jun 1;124(11):2683-9.
  • Fall K, Stark JR, Mucci LA, Chan J, Stampfer MJ, Kurth T, Febbo PG, Kantoff P, Ma J.No association between a polymorphic variant of the IRS-1 gene and prostate cancer risk.Prostate. 2008 Sep 15;68(13):1416-20.
  • Mucci LA,Pawitan Y,Demichelis F,Fall K,Stark JR,Adami HO,Andersson SO,Andren O,Eisenstein A,Holmberg L,Huang W,Kantoff PW,Kim R,Perner S,Stampfer MJ,Johansson JE,Rubin MA.Testing a multigene signature of prostate cancer death in the Swedish Watchful Waiting Cohort.Cancer Epidemiol Biomarkers Prev. 2008 Jul;17(7):1682-8.
  • Mucci LA, Pawitan Y, Demichelis F, Fall K, Stark JR, Adami HO, Andersson SO, Andrn O, Eisenstein AS, Holmberg L, Huang W, Kantoff PW, Perner S, Stampfer MJ, Johansson JE, Rubin MA.Nine-gene molecular signature is not associated with prostate cancer death in a watchful waiting cohort.Cancer Epidemiol Biomarkers Prev. 2008 Jan;17(1):249-51.